Wells Fargo’s Theriva Biologics TOVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$0 Buy
+2
New – ﹤0.01% 7595
2024
Q3
– Sell
-4
Closed -$24 – 7082
2024
Q2
$24 Sell
4
-5
-56% -$44 ﹤0.01% 6475
2024
Q1
$109 Hold
9
– – ﹤0.01% 6634
2023
Q4
$99 Buy
9
+4
+80% +$49 ﹤0.01% 6772
2023
Q3
$67 Buy
5
+1
+25% +$15 ﹤0.01% 6855
2023
Q2
$109 Hold
4
– – ﹤0.01% 6850
2023
Q1
$77 Hold
4
– – ﹤0.01% 6994
2022
Q4
$49 Hold
4
– – ﹤0.01% 7014
2022
Q3
$0 Hold
4
– – ﹤0.01% 7375
2022
Q2
$0 Buy
4
+1
+33% – ﹤0.01% 7496
2022
Q1
$0 Hold
3
– – ﹤0.01% 7803
2021
Q4
$0 Hold
3
– – ﹤0.01% 7660
2021
Q3
$0 Hold
3
– – ﹤0.01% 7538
2021
Q2
$1K Hold
3
– – ﹤0.01% 6757
2021
Q1
$1K Buy
3
+2
+200% +$395 ﹤0.01% 6771
2020
Q4
$0 Buy
+1
New – ﹤0.01% 7020
2020
Q3
– Hold
0
– – – 6903
2020
Q2
– Sell
-1
Closed – – 6826
2020
Q1
$0 Buy
+1
New – ﹤0.01% 6802
2019
Q4
– Hold
0
– – – 6742
2019
Q3
– Hold
0
– – – 6728
2019
Q2
– Hold
0
– – – 6625
2019
Q1
– Hold
0
– – – 6453
2018
Q4
– Hold
0
– – – 6614
2018
Q3
– Hold
0
– – – 6568
2018
Q2
– Hold
0
– – – 6574
2018
Q1
– Hold
0
– – – 6569
2017
Q4
– Hold
0
– – – 6526
2017
Q3
– Hold
0
– – – 6467
2017
Q2
– Sell
-4
Closed -$19.9K – 6451
2017
Q1
$23K Hold
4
– – ﹤0.01% 5682
2016
Q4
$27K Hold
4
– – ﹤0.01% 5551
2016
Q3
$62K Buy
+4
New +$59.9K ﹤0.01% 5188
2016
Q2
– Sell
-1
Closed -$18.8K – 6326
2016
Q1
$16K Sell
1
-6
-86% -$90.2K ﹤0.01% 5571
2015
Q4
$145K Buy
7
+6
+600% +$127K ﹤0.01% 4666
2015
Q3
$25K Buy
+1
New +$24.6K ﹤0.01% 5476
2015
Q2
– Hold
0
– – – 5847
2015
Q1
– Hold
0
– – – 5778
2014
Q4
– Hold
0
– – – 6110
2014
Q3
– Hold
0
– – – 6003
2014
Q2
– Sell
-3
Closed -$64K – 6283
2014
Q1
$64K Buy
+3
New +$62.1K ﹤0.01% 4847
2013
Q3
– Sell
-3
Closed -$48K – 5845
2013
Q2
$48K Hold
3
– – ﹤0.01% 4631

Other funds holding TOVX

Wells Fargo's TOVX Position: Q3 2026 in Review

Wells Fargo opened a new position in Theriva Biologics (TOVX) in Q3 2026: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7595 among its holdings. This is a return to the name: Wells Fargo previously reported a position in TOVX as recently as Q2 2024.

Wells Fargo first reported a position in TOVX in Q2 2013 and has held it in 25 quarters since. The position peaked at $145K in Q4 2015. 26 funds tracked by Wall St. Rank hold TOVX as of Q3 2026.

  • Wells Fargo held 2 shares of Theriva Biologics worth $0 as of Q3 2026.
  • Theriva Biologics was a new Wells Fargo position in Q3 2026.
  • Theriva Biologics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #7595 holding.
  • Wells Fargo first reported a position in Theriva Biologics in Q2 2013 and has held it in 25 quarters since.
  • Wells Fargo's Theriva Biologics position peaked at $145K in Q4 2015.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.